Placental Growth and Maternal Serum Biomarkers in the Prediction of Adverse Pregnancy Outcome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,043
- 试验地点
- 1
- 主要终点
- Small for gestational birth weight (SGA-dichotomous)
研究概览
简要总结
The purpose of this study to determine if measurement of maternal serum biomarkers and evaluation of the placenta by ultrasound can improve prediction of adverse pregnancy outcomes.
详细描述
The placenta is known to play a vital role in maintaining a healthy pregnancy. Placental dysfunction is believed to be a driving factor in a variety of adverse obstetric outcomes, including fetal growth restriction and preeclampsia. Advances in 3D ultrasound have allowed for measurement of placental volumes during pregnancy. It may be that quantitative assessment of early placental growth can help identify pregnancies at risk for adverse outcome. Furthermore, various novel serum analytes have been proposed as predictors of adverse outcome. The investigators seek to prospectively measure placental volume and diameter at 11-14 weeks and 18-24 weeks to determine if placental growth can predict adverse outcome. In addition, the investigators seek to investigate the relationship between placental growth and serum levels of various biomarkers to see if improved detection of adverse outcome can be achieved.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •All singleton gestations presenting for Sequential Screen testing at HUP
- •patients competent to provide verbal informed consent
排除标准
- •Multiple gestations
- •patients not competent to provide informed consent
- •patients found to be too late for the Sequential Screen
- •pregnancy losses 20 weeks gestation
- •major fetal anomalies
- •patient delivering outside of the UPHS
结局指标
主要结局
Small for gestational birth weight (SGA-dichotomous)
时间窗: from 11-14 weeks in pregnancy until delivery (approximately 40 weeks)
Neonatal weight and length are recorded at birth. This information will be retrieved from the medical record post partum.
次要结局
- Includes a composite adverse outcome defined by any of the following: SGA, pre-eclampsia, or perinatal death.(post partum)
